Faculdade Israelita de Ciências da Saúde Albert Einstein - São Paulo (SP) - Brazil.
Hospital Israelita Albert Einstein - São Paulo (SP) - Brazil.
Acta Cir Bras. 2024 Jun 14;39:e392624. doi: 10.1590/acb392624. eCollection 2024.
Acute-on-chronic liver failure (ACLF) is a leading cause of death in cirrhotic patients. This study aims to describe the outcomes of in-patients with ACLF at a liver transplantation (LT) center in Brazil.
Retrospective study analyzing patient data from 2017 to 2022. Re-transplant cases and patients without previous chronic liver disease were excluded. The ACLF diagnosis was based on the European Association for the Study of the Liver-Chronic Liver Failure criteria and assessments repeated on days 3 and 7 after the initial diagnosis.
Among 381 patients, 10.49% (n = 40) were diagnosed with ACLF. Bacterial infection was the most common precipitating factor (45%). Kidney failure occurred in 65% of the cases. The 28-day mortality rate was 35% and varied according to ACLF severity at diagnosis, from single organ failure (ACLF-1) at 22% to three organ failures (ACLF-3) at 60%. Eighteen patients (45%) were transplanted with a 100% 28-day survival rate. For ACLF-3 cases at diagnosis (n = 15), the 28-day and 1-year survival rates with a transplant (n = 4) were 100% and 80%, respectively, and without transplant (n = 11), 10 and 0%, respectively.
ACLF was associated with high mortality rates. LT was an effective therapeutic option, particularly for ACLF-3 cases.
急性肝衰竭(ACLF)是肝硬化患者死亡的主要原因。本研究旨在描述巴西一家肝移植(LT)中心 ACLF 住院患者的结局。
回顾性分析 2017 年至 2022 年期间的患者数据。排除再次移植病例和无既往慢性肝病的患者。ACLF 的诊断基于欧洲肝脏研究协会-慢性肝衰竭标准,并在初始诊断后第 3 天和第 7 天重复评估。
在 381 例患者中,10.49%(n=40)被诊断为 ACLF。细菌感染是最常见的诱发因素(45%)。65%的病例发生肾功能衰竭。28 天死亡率为 35%,且根据诊断时 ACLF 的严重程度而有所不同,从单一器官衰竭(ACLF-1)的 22%到三个器官衰竭(ACLF-3)的 60%。18 例(45%)患者接受移植,28 天存活率为 100%。对于诊断为 ACLF-3 的 15 例患者(n=15),接受移植(n=4)的 28 天和 1 年存活率分别为 100%和 80%,而未接受移植(n=11)的 28 天和 1 年存活率分别为 10%和 0%。
ACLF 死亡率较高。LT 是一种有效的治疗选择,特别是对 ACLF-3 病例。